Pushing boundaries in mRNA vaccine manufacturing

Vikas Gupta talks to Life Sciences Knowledge Hub about ReciBioPharm’s compelling proposition for biotechs

Earlier this year, Vikas Gupta, President of ReciBioPharm, officially introduced ReciBioPharm to the industry at BIO International. In an interview with Life Sciences Knowledge Hub (LSKH), Vikas discussed the compelling proposition that Recipharm’s renamed biologics business unit is now able to offer biotech companies who are looking to progress their therapeutics to the next level.

Recent acquisitions have seen Recipharm expand its specialist CDMO capabilities, now providing a full-service offering, from preclinical to commercial for new biological modalities. This encompasses technologies across innovative therapies: mRNA, plasmid DNA, gene therapy, oncolytic viruses, viral vectors, and microbiome.

In the interview, Vikas shared his views on some of the challenges currently facing biotechs, including the importance of finding the right partner with the necessary expertise, capacity, and facility network to help them develop their therapeutics.  
Vikas also elaborated on ReciBioPharm’s contract with the Massachusetts Insitute of Technology (MIT), as part of an initiative with the FDA to have a fully integrated, continuous production line for mRNA vaccine manufacturing. This three-year project is predicted to accelerate the deployment of mRNA vaccines and novel mRNA therapeutics to patients around the world. This contract recognises ReciBioPharm as forward-thinkers, pushing boundaries in biologics manufacturing.

Finally, LSKH asked Vikas about the growing demand for cell and gene therapy development and ReciBioPharm’s offering in this space. 

To find out more, you can read the interview with Vikas in full here.